Current Report Filing (8-k)
September 05 2019 - 5:02PM
Edgar (US Regulatory)
false0000899866
0000899866
2019-09-05
2019-09-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 5, 2019
ALEXION PHARMACEUTICALS, INC.
-----------------------------------------------------------
(Exact name of registrant as specified in its charter)
|
|
|
|
Delaware
|
000-27756
|
13-3648318
|
------------------
|
------------------
|
---------------
|
(State or other jurisdiction
of incorporation or organization)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
121 Seaport Boulevard, Boston, Massachusetts 02210
---------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (475) 230-2596
|
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
☐
|
Emerging Growth Company
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events
On September 5, 2019, the European Patent Office determined, following examination proceedings, not to grant Alexion Pharmaceuticals, Inc.’s (the “Company”) European patent applications 3124029 and 3167888 which relate to the pharmaceutical compositions of SOLIRIS® (eculizumab) and composition of matter of SOLIRIS® (eculizumab), respectively. The Company will evaluate its option to appeal the European Patent Office’s decision with respect to these patent applications following receipt and review of the written decision.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Date: September 5, 2019
|
ALEXION PHARMACEUTICALS, INC.
|
|
|
|
By: /s/ Doug Barry
|
|
Name: Doug Barry
|
|
Title: Vice President, Corporate Law
|
|
|
|
|
|
|
|
|
|
|
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Sep 2023 to Sep 2024